Recursion Pharmaceuticals Inc
NASDAQ:RXRX

Watchlist Manager
Recursion Pharmaceuticals Inc Logo
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Watchlist
Price: 4.82 USD 2.34%
Market Cap: 2.5B USD

Recursion Pharmaceuticals Inc
Total Other Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Recursion Pharmaceuticals Inc
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Total Other Income
$30k
CAGR 3-Years
N/A
CAGR 5-Years
25%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Other Income
-$4.7B
CAGR 3-Years
-95%
CAGR 5-Years
-27%
CAGR 10-Years
-71%
Gilead Sciences Inc
NASDAQ:GILD
Total Other Income
$90m
CAGR 3-Years
53%
CAGR 5-Years
-24%
CAGR 10-Years
-5%
Amgen Inc
NASDAQ:AMGN
Total Other Income
$2.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Other Income
-$21m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Other Income
$38.9m
CAGR 3-Years
-31%
CAGR 5-Years
-21%
CAGR 10-Years
18%
No Stocks Found

Recursion Pharmaceuticals Inc
Glance View

In the bustling landscape of biotech innovation, Recursion Pharmaceuticals Inc. carves a distinctive niche by marrying the worlds of biology and advanced computational techniques. Founded in 2013, this Salt Lake City-based company embarked on a mission to decode the complex tapestry of disease biology through the lens of data science and machine learning. Recursion's approach centers around its unique platform that integrates automated experimental biology with artificial intelligence to map and navigate the intricate pathways of human cellular biology. By harnessing volumes of data from high-throughput biological experiments, they aim to unearth novel insights into a multitude of diseases, particularly those that have historically evaded effective therapeutic intervention. At the heart of Recursion's business model is its ability to discover potential drug candidates rapidly and efficiently, turning traditional pharmaceutical development on its head. The company generates revenue through strategic partnerships with pharmaceutical giants, leveraging its platform to accelerate drug discovery and development processes. Collaborations often involve sharing the risk and reward of drug discovery, with Recursion providing the technological backbone to sift through vast datasets and identify promising therapeutic compounds. Additionally, Recursion invests in its pipeline of proprietary drug candidates, targeting rare genetic diseases and areas of significant unmet medical need. By aligning cutting-edge technology with the complexities of human biology, Recursion Pharmaceuticals positions itself at the forefront of transforming how diseases are understood and how new treatments are developed.

RXRX Intrinsic Value
3.73 USD
Overvaluation 23%
Intrinsic Value
Price

See Also

What is Recursion Pharmaceuticals Inc's Total Other Income?
Total Other Income
30k USD

Based on the financial report for Dec 31, 2024, Recursion Pharmaceuticals Inc's Total Other Income amounts to 30k USD.

What is Recursion Pharmaceuticals Inc's Total Other Income growth rate?
Total Other Income CAGR 5Y
25%

Back to Top